| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032347647 |
| P356 | DOI | 10.1007/S40262-015-0266-2 |
| P698 | PubMed publication ID | 25850987 |
| P50 | author | Federico Pea | Q38544304 |
| Piergiorgio Cojutti | Q82046186 | ||
| P2093 | author name string | Manjunath P Pai | |
| P2860 | cites work | A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design | Q28476705 |
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q29616834 | ||
| Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. | Q33770046 | ||
| Broad-spectrum β-lactams in obese non-critically ill patients | Q33839225 | ||
| The origin of the "ideal" body weight equations | Q33917345 | ||
| Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa | Q34228382 | ||
| Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability. | Q35206338 | ||
| Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections | Q35759054 | ||
| Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach | Q36396195 | ||
| Augmented renal clearance: implications for antibacterial dosing in the critically ill. | Q37650115 | ||
| Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy | Q37656243 | ||
| Effect of obesity on the pharmacokinetics of drugs in humans | Q37672600 | ||
| Estimating the glomerular filtration rate in obese adult patients for drug dosing. | Q37781448 | ||
| Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? | Q37884104 | ||
| Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target | Q37988861 | ||
| Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients | Q38059857 | ||
| Obesity and kidney disease: potential mechanisms | Q38078543 | ||
| Treatment of multidrug-resistant Gram-negative infections in children | Q38185648 | ||
| Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients | Q40838757 | ||
| Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept | Q42946682 | ||
| Stability of generic brands of meropenem reconstituted in isotonic saline. | Q49046358 | ||
| Quantification of lean bodyweight. | Q50753849 | ||
| Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. | Q54402133 | ||
| Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. | Q54561986 | ||
| Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. | Q54766719 | ||
| Simplified calculation of body-surface area. | Q55060911 | ||
| Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures | Q87459116 | ||
| P433 | issue | 9 | |
| P921 | main subject | obesity | Q12174 |
| pharmacodynamics | Q725307 | ||
| pharmacokinetics | Q323936 | ||
| meropenem | Q421670 | ||
| Gram-negative bacteria | Q632006 | ||
| P304 | page(s) | 933-941 | |
| P577 | publication date | 2015-04-08 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial in | |
| P478 | volume | 54 |
| Q40367930 | Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract |
| Q87256160 | Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring and patient care |
| Q39344408 | Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? |
| Q40494723 | Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections |
| Q39484436 | Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients |
| Q40112541 | Population Pharmacokinetics of High Dose Continuous Infusion Meropenem and Considerations for the Use in the Treatment of Infections due to KPC-Producing Klebsiella pneumoniae |
| Q59263334 | Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age |
| Q87242231 | Therapeutic drug monitoring and pharmacokinetics/pharmacodynamics of antibiotics as useful tools for translational research and personalized medicine |
| Q40172540 | What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? |
Search more.